Phillip K. Darcy

22.2k total citations · 6 hit papers
194 papers, 14.2k citations indexed

About

Phillip K. Darcy is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Phillip K. Darcy has authored 194 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 122 papers in Immunology and 47 papers in Molecular Biology. Recurrent topics in Phillip K. Darcy's work include CAR-T cell therapy research (106 papers), Immune Cell Function and Interaction (75 papers) and Immunotherapy and Immune Responses (67 papers). Phillip K. Darcy is often cited by papers focused on CAR-T cell therapy research (106 papers), Immune Cell Function and Interaction (75 papers) and Immunotherapy and Immune Responses (67 papers). Phillip K. Darcy collaborates with scholars based in Australia, United States and Canada. Phillip K. Darcy's co-authors include Michael H. Kershaw, Mark J. Smyth, Paul A. Beavis, Jennifer A. Westwood, John Stagg, Sherene Loi, Clare Y. Slaney, Joseph A. Trapani, Liza B. John and Christel Devaud and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Phillip K. Darcy

188 papers receiving 14.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

2015 638 citations Peter Savas, Phillip K. Darcy et al. profile →
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

2013 571 citations Liza B. John, Christel Devaud et al. Clinical Cancer Research profile →
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

2017 434 citations Phillip K. Darcy et al. profile →
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →
Gene-engineered T cells for cancer therapy

2013 387 citations Michael H. Kershaw, Jennifer A. Westwood et al. profile →
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

2013 387 citations Sherene Loi, Paul A. Beavis et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Phillip K. Darcy

Since Specialization

Citations

This map shows the geographic impact of Phillip K. Darcy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip K. Darcy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip K. Darcy more than expected).

Fields of papers citing papers by Phillip K. Darcy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip K. Darcy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip K. Darcy. The network helps show where Phillip K. Darcy may publish in the future.

Co-authorship network of co-authors of Phillip K. Darcy

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip K. Darcy. A scholar is included among the top collaborators of Phillip K. Darcy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip K. Darcy. Phillip K. Darcy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity 2021 ·Cancer Discovery ·Florian Wiede, Kun‐Hui Lu, Xin Du, Mara N. Zeissig, (unknown), Pei Kee Goh, Chrysovalantou E. Xirouchaki, (unknown), (unknown), Kevin Sek, Roger J. Daly, Paul A. Beavis, Phillip K. Darcy, Nicholas K. Tonks, Tony Tiganis	90
2	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot 2020 ·Journal for ImmunoTherapy of Cancer ·Simon P. Keam, Heloise M. Halse, Thu Quynh Nguyen, Minyu Wang, (unknown), Catherine Mitchell, Franco Caramia, David J. Byrne, Sue Haupt, Georgina L. Ryland, Phillip K. Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott Williams, Paul J. Neeson	51
3	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade breakdown → 2019 ·Clinical Cancer Research ·Imran G. House, Peter Savas, Junyun Lai, Amanda X. Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis	412
4	Antagonism of IAPs Enhances CAR T-cell Efficacy 2019 ·Cancer Immunology Research ·Jessica Michie, Paul A. Beavis, Andrew J. Freeman, Stephin J. Vervoort, Kelly M. Ramsbottom, Vignesh Narasimhan, Emily J. Lelliott, Najoua Lalaoui, Robert G. Ramsay, Ricky W. Johnstone, John Silke, Phillip K. Darcy, Ilia Voskoboinik, Conor J. Kearney, Jane Oliaro	77
5	Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity 2018 ·Proceedings of the National Academy of Sciences ·Alexander J. Davenport, Ryan Cross, Katherine A. Watson, Yi‐Han Liao, Wei Shi, H. Miles Prince, Paul A. Beavis, Joseph A. Trapani, Michael H. Kershaw, David Ritchie, Phillip K. Darcy, Paul J. Neeson, Misty R. Jenkins	244
6	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells 2018 ·Cancer Immunology Research ·Paul A. Beavis, Melissa A. Henderson, Lauren Giuffrida, Alexander J. Davenport, Emma V. Petley, Imran G. House, Junyun Lai, Kevin Sek, Nicole Milenkovski, Liza B. John, Sherly Mardiana, Clare Y. Slaney, Joseph A. Trapani, Sherene Loi, Michael H. Kershaw, Nicole M. Haynes, Phillip K. Darcy	51
7	Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC 2017 ·Cancer Immunology Research ·Natasha K. Brockwell, Katie L. Owen, Damien Zanker, Alex Spurling, Jai Rautela, Hendrika M. Duivenvoorden, Nikola Baschuk, Franco Caramia, Sherene Loi, Phillip K. Darcy, Elgene Lim, Belinda S. Parker	60
8	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells 2017 ·Cancer Research ·Sherly Mardiana, Liza B. John, Melissa A. Henderson, Clare Y. Slaney, Bianca von Scheidt, Lauren Giuffrida, Alexander J. Davenport, Joseph A. Trapani, Paul J. Neeson, Sherene Loi, Nicole M. Haynes, Michael H. Kershaw, Paul A. Beavis, Phillip K. Darcy	63
9	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors 2017 ·Cancer Research ·(unknown), Eva Vidacs, Stephin J. Vervoort, Jason Li, Misty R. Jenkins, Kelly M. Ramsbottom, Joseph A. Trapani, Mark J. Smyth, Phillip K. Darcy, Peter Atadja, Michael A. Henderson, Ricky W. Johnstone, Nicole M. Haynes	25
10	Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer 2017 ·Cancer Research ·Zhi L. Teo, (unknown), Sathana Dushyanthen, Franco Caramia, Peter Savas, (unknown), Magnus Zethoven, Balaji Virassamy, Stephen J. Luen, Grant A. McArthur, Wayne A. Phillips, Phillip K. Darcy, Sherene Loi	148
11	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting 2016 ·Clinical Cancer Research ·Clare Y. Slaney, Bianca von Scheidt, Alexander J. Davenport, Paul A. Beavis, Jennifer A. Westwood, Sherly Mardiana, David C. Tscharke, Sarah Ellis, H. Miles Prince, Joseph A. Trapani, Ricky W. Johnstone, Mark J. Smyth, Michele W.L. Teng, (unknown), Zhiya Yu, Steven A. Rosenberg, Nicholas P. Restifo, Paul J. Neeson, Phillip K. Darcy, Michael H. Kershaw	89
12	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells 2015 ·Cancer Immunology Research ·Alexander J. Davenport, Misty R. Jenkins, Ryan Cross, Carmen S. Yong, H. Miles Prince, David Ritchie, Joseph A. Trapani, Michael H. Kershaw, Phillip K. Darcy, Paul J. Neeson	112
13	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses 2015 ·Cancer Immunology Research ·Paul A. Beavis, Nicole Milenkovski, Melissa A. Henderson, Liza B. John, Bertrand Allard, Sherene Loi, Michael H. Kershaw, John Stagg, Phillip K. Darcy	270
14	CD73-Deficient Mice Are Resistant to Carcinogenesis 2012 ·Cancer Research ·John Stagg, Paul A. Beavis, Upulie Divisekera, Mira C.P. Liu, Andreas Möller, Phillip K. Darcy, Mark J. Smyth	174
15	Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer 2012 ·Cancer Research ·Liza B. John, (unknown), Jacqueline K. Flynn, Alison C. West, Christel Devaud, Connie P.M. Duong, Trina J. Stewart, (unknown), Zong Sheng Guo, David L. Bartlett, Mark J. Smyth, Michael H. Kershaw, Phillip K. Darcy	92
16	CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis 2011 ·Cancer Research ·John Stagg, Upulie Divisekera, Helene Duret, Tim Sparwasser, Michele W.L. Teng, Phillip K. Darcy, Mark J. Smyth	320
17	Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion 2010 ·Cancer Research ·Michele W.L. Teng, Jeremy B. Swann, Bianca von Scheidt, Janelle Sharkey, Nadeen Zerafa, Nicole M. McLaughlin, Tomoyuki Yamaguchi, Shimon Sakaguchi, Phillip K. Darcy, Mark J. Smyth	58
18	Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice 2009 ·Clinical Cancer Research ·Jennifer A. Westwood, Nicole M. Haynes, Janelle Sharkey, Nicole M. McLaughlin, Hollie J. Pegram, Reto A. Schwendener, Mark J. Smyth, Phillip K. Darcy, Michael H. Kershaw	20
19	Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells 2007 ·Cancer Research ·Maria Moeller, Michael H. Kershaw, (unknown), Jennifer A. Westwood, Joseph A. Trapani, Mark J. Smyth, Phillip K. Darcy	55
20	Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice 2007 ·Cancer Research ·Michele W.L. Teng, Jennifer A. Westwood, Phillip K. Darcy, Janelle Sharkey, Moriya Tsuji, Richard W. Franck, Steven A. Porcelli, Gurdyal S. Besra, Kazuyoshi Takeda, Hideo Yagita∥, Michael H. Kershaw, Mark J. Smyth	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact